Characterization of FGFR signaling pathway as therapeutic targets for sarcoma patients by Wen-Ya Zhou, Hong Zheng, Xiao-Ling Du, Ji-Long Yang

Subjects: Get full text

Calciphylaxis associated with the fibroblast growth factor receptor inhibitor erdafitinib by Paul Macklis, MS, Catherine Chung, MD, Benjamin Kaffenberger, MD

Subjects: Get full text

Metastatic Urothelial Carcinoma: Have We Take the Road to the Personalized Medicine? by Marco Audisio, Consuelo Buttigliero, Fabio Turco, Marco Donatello Delcuratolo, Chiara Pisano, Elena Parlagreco, Rosario Francesco Di Stefano, Lavinia Di Prima, Veronica Crespi, Giovanni Farinea, Massimiliano Cani, Marcello Tucci

Subjects: Get full text

Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells by Sergei Boichuk, Pavel Dunaev, Ilshat Mustafin, Shinjit Mani, Kirill Syuzov, Elena Valeeva, Firuza Bikinieva, Aigul Galembikova

Subjects: Get full text

Recent Advances in Tumor Therapy Targeting FGFR by ZHANG Jing, WANG Chen, GU Baohong, ZHANG Yaqing, CHEN Hao

Subjects: Get full text

Fibroblast growth factor receptor signalling dysregulation and targeting in breast cancer by Chiara Francavilla, Ciara S. O'Brien

Subjects: Get full text

Case Report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma by Zhuochao Zhang, Zhuochao Zhang, Gaofei Wang, Lei Du, Jie Zhao, Lichao Pan, Lichao Pan, Gong Zhang, Gong Zhang, Gong Zhang, Fei Wang, Fei Wang, Rong Liu, Rong Liu

Subjects: Get full text

Advances in Therapy for Urothelial and Non-Urothelial Subtype Histologies of Advanced Bladder Cancer: From Etiology to Current Development by Whi-An Kwon, Ho Kyung Seo, Geehyun Song, Min-Kyung Lee, Weon Seo Park

Subjects: Get full text

FGFR3–TACC3: A novel gene fusion in cervical cancer by Benedito A. Carneiro, Julia A. Elvin, Suneel D. Kamath, Siraj M. Ali, Ajit S. Paintal, Alvaro Restrepo, Emily Berry, Francis J. Giles, Melissa L. Johnson

Subjects: Get full text

Targeting the cancer cells and cancer‐associated fibroblasts with next‐generation FGFR inhibitors in prostate cancer co‐culture models by Syeda Afshan, Yu Gang Kim, Jesse Mattsson, Malin Åkerfelt, Pirkko Härkönen, Martin Baumgartner, Matthias Nees

Subjects: Get full text

State-of-the-Art of Monoclonal Antibodies for the Treatment of Gastric Cancer by Basile D, Simionato F, Cappetta A, Garattini SK, Roviello G, Aprile G

Subjects: Get full text

FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target? by Csongor G. Lengyel, Sadaqat Hussain, Andreas Seeber, Sara Jamil Nidhamalddin, Dario Trapani, Baker S. Habeeb, Essam Elfaham, Syed Ayub Mazher, Fahmi Seid, Shah Z. Khan, Khalid El Bairi, Andrew Odhiambo, Sara C. Altuna, Angelica Petrillo

Subjects: Get full text

Targeting PI3K, FGFR, CDK4/6 Signaling Pathways Together With Cytostatics and Radiotherapy in Two Medulloblastoma Cell Lines by Monika Lukoseviciute, Henrietta Maier, Eleni Poulou-Sidiropoulou, Erika Rosendahl, Stefan Holzhauser, Tina Dalianis, Ourania N. Kostopoulou

Subjects: Get full text

Multifocal serous retinopathy with pemigatinib therapy for metastatic colon adenocarcinoma by Oleg Alekseev, Effy Ojuok, Scott Cousins

Subjects: “…FGFR inhibitor…”
Get full text

Design, synthesis and biological evaluation of pyrazolo[3,4-d]pyridazinone derivatives as covalent FGFR inhibitors by Xiaowei Wu, Mengdi Dai, Rongrong Cui, Yulan Wang, Chunpu Li, Xia Peng, Jihui Zhao, Bao Wang, Yang Dai, Dan Feng, Tianbiao Yang, Hualiang Jiang, Meiyu Geng, Jing Ai, Mingyue Zheng, Hong Liu

Subjects: Get full text

Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial by Joon Oh Park, Yin-Hsun Feng, Wu-Chou Su, Do-Youn Oh, Bhumsuk Keam, Lin Shen, Sang-We Kim, Xiufeng Liu, Huimin Liao, Min Qing, Chong Zhang, Jiaqi Qian, Xiaodan Tang, Peng Li, Spyros Triantos, Hussein Sweiti

Subjects: Get full text

Fibroblast Growth Factor Receptor 1-4 Genetic Aberrations as Clinically Relevant Biomarkers in Squamous Cell Lung Cancer by Joanna Moes-Sosnowska, Joanna Chorostowska-Wynimko

Subjects: Get full text

Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors by Eunhae Shin, Dong Hui Lim, Jisang Han, Do-Hyun Nam, Keunchil Park, Myung-Ju Ahn, Won Ki Kang, Jeeyun Lee, Jin Seok Ahn, Se-Hoon Lee, Jong-Mu Sun, Hyun Ae Jung, Tae-Young Chung

Subjects: Get full text

Reductions in Myeloid-Derived Suppressor Cells and Lung Metastases using AZD4547 Treatment of a Metastatic Murine Breast Tumor Model by Li Liu, Ting Hong Ye, Yuan Ping Han, Hang Song, Yong Kui Zhang, Yong Xia, Ning Yu Wang, Ying Xiong, Xue Jiao Song, Yong Xia Zhu, De Liang Li, Jun Zeng, Kai Ran, Cui Ting Peng, Yu Quan Wei, Luo Ting Yu

Subjects: “…FGFR inhibitor…”
Get full text

Therapies targeting triple-negative breast cancer: a perspective on anti-FGFR by Jinhao Chen, Jinhao Chen, Jinhao Chen, Qianru Wang, Qianru Wang, Hongyan Wu, Hongyan Wu, Xiaofei Huang, Xiaofei Huang, Chunyu Cao, Chunyu Cao

Subjects: Get full text